Translink Corporate Finance in The Netherlands advised UD-Vet, a leading provider of veterinary practice equipment and other veterinary imaging modalities, on the sale to IMV Technologies, a global leader in animal artificial insemination and veterinary imaging.
Translink Corporate Finance Benelux advised rond and PurpleHRM on the partnership with Axians, the ICT brand of VINCI Energies.
Translink Corporate Finance in France advised IK Partners on the acquisition of a minority stake in OCTIME Group, a leading French SaaS workforce management company.
Translink Corporate Finance in Denmark acted as the advisor to the owners of Danish MouldShop A/S, MouldPro A/S and British MouldShop Ltd, on the sale to Groupe Baelen.
Translink Corporate Finance in France and Norway acted as the M&A advisor to Visma, Europe’s leading provider of mission-critical software, on its investment in MyCompanyFiles, a prominent French platform specialising in secure document and information exchange for accounting firms.
Translink Corporate Finance in France advised the shareholders of Retrofleet on their sale to the CBM Group. The Group acquires a majority share of the Retrofleet company.
Translink Corporate Finance in Norway and Translink Corporate Finance in France acted as the advisors to Visma in its acquisition of Chaintrust. Through this acquisition, Visma further strengthens its presence in France.
Following a process led by Translink Corporate Finance in France, Elyan Partners has entered into exclusive negotiations for the acquisition of a majority stake in Stordata. This transaction would enable the reinvestment of the current executive shareholders, Olivier Teichman, Executive Chairman and co-founder, and Marc Michel, CEO and co-founder.
Translink Corporate Finance acted as advisor to the shareholders of Royston Labels Limited, a UK based manufacturer of premium self-adhesive labels.
Established in 1992, the Company operates from a state-of-the-art manufacturing facility in Royston, United Kingdom.
In the healthcare sector, renowned for its resilience and appeal to astute investors, a distinctive shift is underway. Investment funds have assumed a prominent role in M&A activities, fostering R&D projects and catalysing innovation in medical devices.
